Skip to main content
SpringerLink
Log in

Treatment of Early-Stage (Stage I and II) Non-Small Cell Lung Cancer

  • Chapter
  • First Online:
Lung Cancer

Part of the book series: Respiratory Medicine ((RM))

  • 375 Accesses

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide. The TNM classification system is used to stage lung cancer, and according to the eighth edition of AJCC, early stage non-small cell lung cancer (NSCLC) includes malignancies that are classified as stage IA (T1miN0M0 or T1N0M0), IB (T2aN0M0), IIA (T2bN0M0), and IIB (T1-2N0M0 or T3N0M0). The treatment of choice for early-stage NSCLC in patients who are deemed eligible for surgery involves resection of the tumor. The eligibility for surgery is determined based on the patient’s functional capacity and pulmonary function tests. The extent of the pulmonary resection is determined by the location and size of the tumor. Lobectomy is still considered the mainstay surgical treatment for early-stage NSCLC, with pneumonectomy and sleeve resection being considered when tumor location and size require it. Interestingly, contemporary evidence suggests that segmentectomy might offer equivalent outcomes in terms of overall survival compared to lobectomy for <2 cm tumors. The benefit of adjuvant chemotherapy in early-stage lung cancer is controversial. It is currently recommended in patients with stage II NSCLC that have negative surgical margins and is optional in high-risk histology with stage IB NSCLC. Stereotactic body radiotherapy (SBRT) is considered an alternative definitive treatment for NSCLC, and it is typically utilized in patients who were not deemed eligible for surgery or who elect to undergo nonoperative management. Overall, patients with early-stage NSCLC have encouraging 5-year overall survival outcomes ranging from 92 to 53% depending on the stage of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lung Cancer Statistics|How Common is Lung Cancer?. Accessed 8 Oct 2022. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/CAAC.21442.

    Article  PubMed  Google Scholar 

  3. Thomas KW, Gould MK. Tumor, node, metastasis (TNM) staging system for lung cancer—UpToDate. Accessed 2 Oct 2022. https://www.uptodate.com/contents/tumor-node-metastasis-tnm-staging-system-for-lung-cancer.

  4. Non-small Cell Lung Cancer Staging|Stages of Lung Cancer. Accessed 2 Oct 2022. https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/staging-nsclc.html.

  5. Dyas AR, King RW, Ghanim AF, Cerfolio RJ. Clinical misstagings and risk factors of occult nodal disease in non-small cell lung cancer. Ann Thorac Surg. 2018;106(5):1492–8. https://doi.org/10.1016/J.ATHORACSUR.2018.05.045.

    Article  PubMed  Google Scholar 

  6. NCCN Clinical practice guidelines in oncology. Non-Small Cell Lung Cancer Version 1.2023. Accessed 12 Sep 2022. https://www.nccn.org/guidelines/recently-published-guidelines.

  7. Pathak R, Hoag JR, Goldberg SB, Monsalve AF, Resio B, Boffa DJ. Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC. J Clin Oncol. 2019;37(15_suppl):8519. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.8519.

    Article  Google Scholar 

  8. Tsutani Y, Imai K, Ito H, et al. Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: a multicenter study. J Clin Oncol. 2019;37(15_suppl):8500. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.8500.

    Article  Google Scholar 

  9. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–9. https://doi.org/10.1200/JCO.2007.13.9030.

    Article  PubMed  Google Scholar 

  10. Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American society of clinical oncology/cancer care Ontario clinical practice guideline update. J Clin Oncol. 2017;35(25):2960–74. https://doi.org/10.1200/JCO.2017.72.4401.

    Article  PubMed  Google Scholar 

  11. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–97. https://doi.org/10.1056/NEJMOA043623.

    Article  CAS  PubMed  Google Scholar 

  12. Douillard JY, Rosell R, de Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27. https://doi.org/10.1016/S1470-2045(06)70804-X.

    Article  CAS  PubMed  Google Scholar 

  13. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 2003;95(19):1453–61. https://doi.org/10.1093/JNCI/DJG059.

    Article  CAS  PubMed  Google Scholar 

  14. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60. https://doi.org/10.1056/NEJMOA031644.

    Article  PubMed  Google Scholar 

  15. Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. https://doi.org/10.1056/NEJMOA1809064/SUPPL_FILE/NEJMOA1809064_DATA-SHARING.PDF.

    Article  CAS  PubMed  Google Scholar 

  16. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR -mutated non–small-cell lung cancer. N Engl J Med. 2020;383(18):1711–23. https://doi.org/10.1056/NEJMOA2027071/SUPPL_FILE/NEJMOA2027071_DATA-SHARING.PDF.

    Article  CAS  PubMed  Google Scholar 

  17. Stewart LA, Burdett S, Parmar MKB, et al. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352(9124):257–63. https://doi.org/10.1016/S0140-6736(98)06341-7.

    Article  Google Scholar 

  18. Douillard JY, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol. 2005;23(16_suppl):7013. https://doi.org/10.1200/JCO.2005.23.16_SUPPL.7013.

    Article  Google Scholar 

  19. le Pechoux C, Pourel N, Barlesi F, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(1):104–14. https://doi.org/10.1016/S1470-2045(21)00606-9.

    Article  PubMed  Google Scholar 

  20. Prezzano KM, Ma SJ, Hermann GM, Rivers CI, Gomez-Suescun JA, Singh AK. Stereotactic body radiation therapy for non-small cell lung cancer: a review. World J Clin Oncol. 2019;10(1):14. https://doi.org/10.5306/WJCO.V10.I1.14.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6. https://doi.org/10.1001/JAMA.2010.261.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Herth F, Becker HD, LoCicero J, Ernst A. Endobronchial ultrasound in therapeutic bronchoscopy. Eur Respir J. 2002;20(1):118–21. https://doi.org/10.1183/09031936.02.01642001.

    Article  CAS  PubMed  Google Scholar 

  23. Moore W, Talati R, Bhattacharji P, Bilfinger T. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol. 2015;26(3):312–9. https://doi.org/10.1016/J.JVIR.2014.12.006.

    Article  PubMed  Google Scholar 

  24. Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival rates after thermal ablation versus stereotactic radiation therapy for stage 1 non-small cell lung cancer: A National Cancer Database Study. Radiology. 2018;289(3):862–70. https://doi.org/10.1148/RADIOL.2018180979.

    Article  PubMed  Google Scholar 

  25. Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(18):1813–22. https://doi.org/10.1200/JCO.2017.74.0720.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e166S. https://doi.org/10.1378/CHEST.12-2395.

    Article  CAS  PubMed  Google Scholar 

  27. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009;34(1):17–41. https://doi.org/10.1183/09031936.00184308.

    Article  CAS  PubMed  Google Scholar 

  28. Armstrong P, Congleton J, Fountain SW, et al. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax. 2001;56(2):89–108. https://doi.org/10.1136/THORAX.56.2.89.

    Article  Google Scholar 

  29. Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest. 2003;123(6):2096–103. https://doi.org/10.1378/CHEST.123.6.2096.

    Article  PubMed  Google Scholar 

  30. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 SUPPL):e93S–e120S. https://doi.org/10.1378/CHEST.12-2351/ATTACHMENT/62CD9F06-7D2E-4FCF-A041-2B5F781CEFFE/MMC4.XLS.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Altorki NK, Kamel MK, Narula N, et al. Anatomical segmentectomy and wedge resections are associated with comparable outcomes for patients with small cT1N0 non-small cell lung cancer. J Thorac Oncol. 2016;11(11):1984–92. https://doi.org/10.1016/J.JTHO.2016.06.031.

    Article  PubMed  Google Scholar 

  32. Altorki NK, Wang X, Wigle D, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018;6(12):915–24. https://doi.org/10.1016/S2213-2600(18)30411-9.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607–17. https://doi.org/10.1016/S0140-6736(21)02333-3.

    Article  CAS  PubMed  Google Scholar 

  34. Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg. 2003;76(6):1782–8. https://doi.org/10.1016/S0003-4975(03)01243-8.

    Article  PubMed  Google Scholar 

  35. Oka S, Matsumiya H, Shinohara S, et al. Total or partial vertebrectomy for lung cancer invading the spine. Ann Med Surg. 2016;12:1. https://doi.org/10.1016/J.AMSU.2016.10.002.

    Article  Google Scholar 

  36. Borri A, Leo F, Veronesi G, et al. Extended pneumonectomy for non-small cell lung cancer: morbidity, mortality, and long-term results. J Thorac Cardiovasc Surg. 2007;134(5):1266–72. https://doi.org/10.1016/J.JTCVS.2007.01.021.

    Article  PubMed  Google Scholar 

  37. Steinfort DP, Vincent J, Heinze S, Antippa P, Irving LB. Comparative effectiveness of radial probe endobronchial ultrasound versus CT-guided needle biopsy for evaluation of peripheral pulmonary lesions: a randomized pragmatic trial. Respir Med. 2011;105(11):1704–11. https://doi.org/10.1016/J.RMED.2011.08.008.

    Article  PubMed  Google Scholar 

  38. El-Bayoumi E, Silvestri GA. Bronchoscopy for the diagnosis and staging of lung cancer. Semin Respir Crit Care Med. 2008;29(3):261–70. https://doi.org/10.1055/S-2008-1076746.

    Article  PubMed  Google Scholar 

  39. Dooms C, Seijo L, Gasparini S, Trisolini R, Ninane V, Tournoy KG. Diagnostic bronchoscopy: state of the art. Eur Respir Rev. 2010;19(117):229–36. https://doi.org/10.1183/09059180.00005710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Maldonado F, Edell ES, Barron PJ, et al. Novel bronchoscopic strategies for the diagnosis of peripheral lung lesions: present techniques and future directions. Respirology. 2014;19(5):636–44. https://doi.org/10.1111/RESP.12301.

    Article  Google Scholar 

  41. Wiener RS, Schwartz LM, Woloshin S, Gilbert WH. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med. 2011;155(3):137–44. https://doi.org/10.7326/0003-4819-155-3-201108020-00003.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Howington JA. The role of VATS for staging and diagnosis in patients with non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2007;19(3):212–6. https://doi.org/10.1053/J.SEMTCVS.2007.07.007.

    Article  PubMed  Google Scholar 

  43. Giroux DJ, Rami-Porta R, Chansky K, et al. The IASLC lung cancer staging project data elements for the prospective project. J Thorac Oncol. 2009;4(6):679–83. https://doi.org/10.1097/JTO.0b013e3181a52370.

    Article  PubMed  Google Scholar 

  44. Purandare NC, Rangarajan V. Imaging of lung cancer: implications on staging and management. Indian J Radiol Imaging. 2015;25(2):109. https://doi.org/10.4103/0971-3026.155831.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Verschakelen JA, Bogaert J, de Wever W. Computed tomography in staging for lung cancer. Eur Respir J. 2002;19(35 suppl):40S–8s. https://doi.org/10.1183/09031936.02.00270802.

    Article  Google Scholar 

  46. de Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J. 2007;29(5):995–1002. https://doi.org/10.1183/09031936.00119106.

    Article  PubMed  Google Scholar 

  47. Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007;17(1):23–32. https://doi.org/10.1007/S00330-006-0284-4.

    Article  PubMed  Google Scholar 

  48. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139(11):879. https://doi.org/10.7326/0003-4819-139-11-200311180-00013.

    Article  PubMed  Google Scholar 

  49. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 SUPPL):e211S–50S. https://doi.org/10.1378/CHEST.12-2355/ATTACHMENT/19E9A976-6185-4CE8-AAEE-B4A713FEACCA/MMC1.DOCX.

    Article  PubMed  Google Scholar 

  50. Mentzer SJ. Mediastinoscopy, thoracoscopy, and video-assisted thoracic surgery in the diagnosis and staging of lung cancer. Hematol Oncol Clin North Am. 1997;11(3):435–47. https://doi.org/10.1016/S0889-8588(05)70442-1.

    Article  CAS  PubMed  Google Scholar 

  51. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–71. https://doi.org/10.1378/CHEST.08-0978.

    Article  PubMed  Google Scholar 

  52. Detterbeck F, Puchalski J, Rubinowitz A, Cheng D. Classification of the thoroughness of mediastinal staging of lung cancer. Chest. 2010;137(2):436–42. https://doi.org/10.1378/CHEST.09-1378.

    Article  PubMed  Google Scholar 

  53. Dezube AR, Hirji S, Shah R, et al. Pre-COVID-19 national mortality trends in open and video-assisted lobectomy for non-small cell lung cancer. J Surg Res. 2022;274:213–23. https://doi.org/10.1016/J.JSS.2021.12.047.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Villamizar NR, Darrabie MD, Burfeind WR, et al. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. J Thorac Cardiovasc Surg. 2009;138(2):419–25. https://doi.org/10.1016/J.JTCVS.2009.04.026.

    Article  PubMed  Google Scholar 

  55. Paul S, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg. 2010;139(2):366–78. https://doi.org/10.1016/J.JTCVS.2009.08.026.

    Article  PubMed  Google Scholar 

  56. Fernandez FG, Kosinski AS, Burfeind W, et al. The society of thoracic surgeons lung cancer resection risk model: higher quality data and superior outcomes. Ann Thorac Surg. 2016;102(2):370–7. https://doi.org/10.1016/J.ATHORACSUR.2016.02.098.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Ceppa DP, Kosinski AS, Berry MF, et al. Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons database analysis. Ann Surg. 2012;256(3):487–93. https://doi.org/10.1097/SLA.0B013E318265819C.

    Article  PubMed  Google Scholar 

  58. Zhang L, Gao S. Robot-assisted thoracic surgery versus open thoracic surgery for lung cancer: a system review and meta-analysis. Int J Clin Exp Med. 2015;8(10):17804; /pmc/articles/PMC4694272/. Accessed 2 Oct 2022.

    PubMed  PubMed Central  Google Scholar 

  59. Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016;17(6):836–44. https://doi.org/10.1016/S1470-2045(16)00173-X.

    Article  PubMed  Google Scholar 

  60. Yang CFJ, Kumar A, Klapper JA, et al. A national analysis of long-term survival following thoracoscopic versus open lobectomy for stage I non-small-cell lung cancer. Ann Surg. 2019;269(1):163–71. https://doi.org/10.1097/SLA.0000000000002342.

    Article  PubMed  Google Scholar 

  61. Lim EKS, Batchelor TJP, Dunning J, et al. Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: one-year results from a randomized controlled trial (VIOLET). J Clin Oncol. 2021;39(15_suppl):8504. https://doi.org/10.1200/JCO.2021.39.15_SUPPL.8504.

    Article  Google Scholar 

  62. Cui Y, Grogan EL, Deppen SA, et al. Mortality for robotic- vs video-assisted lobectomy-treated stage I non-small cell lung cancer patients. JNCI Cancer Spectr. 2020;4(5):pkaa028. https://doi.org/10.1093/JNCICS/PKAA028.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Yang HX, Woo KM, Sima CS, et al. Long-term survival based on the surgical approach to lobectomy for clinical stage I nonsmall cell lung cancer: comparison of robotic, video-assisted thoracic surgery, and thoracotomy lobectomy. Ann Surg. 2017;265(2):431–7. https://doi.org/10.1097/SLA.0000000000001708.

    Article  PubMed  Google Scholar 

  64. Ma J, Li X, Zhao S, Wang J, Zhang W, Sun G. Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis. BMC Cancer. 2021;21(1):1–16. https://doi.org/10.1186/S12885-021-08241-5/FIGURES/8.

    Article  Google Scholar 

  65. Paul S, Jalbert J, Isaacs AJ, Altorki NK, Isom OW, Sedrakyan A. Comparative effectiveness of robotic-assisted vs thoracoscopic lobectomy. Chest. 2014;146(6):1505–12. https://doi.org/10.1378/CHEST.13-3032.

    Article  PubMed  Google Scholar 

  66. Swanson SJ, Miller DL, McKenna RJ, et al. Comparing robot-assisted thoracic surgical lobectomy with conventional video-assisted thoracic surgical lobectomy and wedge resection: results from a multihospital database (premier). J Thorac Cardiovasc Surg. 2014;147(3):929–37. https://doi.org/10.1016/J.JTCVS.2013.09.046.

    Article  PubMed  Google Scholar 

  67. Gonzalez-Rivas D, Paradela M, Fernandez R, et al. Uniportal video-assisted thoracoscopic lobectomy: two years of experience. Ann Thorac Surg. 2013;95(2):426–32. https://doi.org/10.1016/J.ATHORACSUR.2012.10.070.

    Article  PubMed  Google Scholar 

  68. Ng CSH, Kim HK, Wong RHL, Yim APC, Mok TSK, Choi YH. Single-port video-assisted thoracoscopic major lung resections: experience with 150 consecutive cases. Thorac Cardiovasc Surg. 2016;64(4):348–53. https://doi.org/10.1055/S-0034-1396789.

    Article  PubMed  Google Scholar 

  69. Rocco G, Martucci N, la Manna C, et al. Ten-year experience on 644 patients undergoing single-port (uniportal) video-assisted thoracoscopic surgery. Ann Thorac Surg. 2013;96(2):434–8. https://doi.org/10.1016/J.ATHORACSUR.2013.04.044.

    Article  PubMed  Google Scholar 

  70. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85. https://doi.org/10.1056/NEJMOA2202170/SUPPL_FILE/NEJMOA2202170_DATA-SHARING.PDF.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Kandathil A, Chamarthy M. Pulmonary vascular anatomy & anatomical variants. Cardiovasc Diagn Ther. 2018;8(3):201. https://doi.org/10.21037/CDT.2018.01.04.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Linden PA, D’Amico TA, Perry Y, et al. Quantifying the safety benefits of wedge resection: a society of thoracic surgery database propensity-matched analysis. Ann Thorac Surg. 2014;98(5):1705–12. https://doi.org/10.1016/J.ATHORACSUR.2014.06.017.

    Article  PubMed  Google Scholar 

  73. Schuchert MJ, Abbas G, Pennathur A, et al. Sublobar resection for early-stage lung cancer. Semin Thorac Cardiovasc Surg. 2010;22(1):22–31. https://doi.org/10.1053/J.SEMTCVS.2010.04.004.

    Article  PubMed  Google Scholar 

  74. Kent M, Landreneau R, Mandrekar S, et al. Segmentectomy versus wedge resection for non-small cell lung cancer in high-risk operable patients. Ann Thorac Surg. 2013;96(5):1747–55. https://doi.org/10.1016/J.ATHORACSUR.2013.05.104.

    Article  PubMed  Google Scholar 

  75. El-Sherif A, Fernando HC, Santos R, et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann Surg Oncol. 2007;14(8):2400–5. https://doi.org/10.1245/S10434-007-9421-9.

    Article  PubMed  Google Scholar 

  76. Gudbjartsson T, Gyllstedt E, Pikwer A, Jönsson P. Early surgical results after pneumonectomy for non-small cell lung cancer are not affected by preoperative radiotherapy and chemotherapy. Ann Thorac Surg. 2008;86(2):376–82. https://doi.org/10.1016/j.athoracsur.2008.04.013.

    Article  PubMed  Google Scholar 

  77. Shi W, Zhang W, Sun H, Shao Y. Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis. World J Surg Oncol. 2012;10:265. https://doi.org/10.1186/1477-7819-10-265.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American college of surgery oncology group Z0030 trial. J Thorac Cardiovasc Surg. 2011;141(3):662–70. https://doi.org/10.1016/J.JTCVS.2010.11.008.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Manser R, Wright G, Hart D, et al. Surgery for early stage non-small cell lung cancer. Cochrane Database Syst Rev. 2005;2005(1):CD004699. https://doi.org/10.1002/14651858.CD004699.PUB2.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009.

    Article  PubMed  Google Scholar 

  81. Pisters KMW, le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol. 2005;23(14):3270–8. https://doi.org/10.1200/JCO.2005.11.478.

    Article  CAS  PubMed  Google Scholar 

  82. Saynak M, Veeramachaneni NK, Hubbs JL, et al. Local failure after complete resection of N0-1 non-small cell lung cancer. Lung Cancer. 2011;71(2):156–65. https://doi.org/10.1016/J.LUNGCAN.2010.06.001.

    Article  PubMed  Google Scholar 

  83. Choi MS, Park JS, Kim HK, et al. Analysis of 1,067 cases of video-assisted thoracic surgery lobectomy. Korean J Thorac Cardiovasc Surg. 2011;44(2):169–77. https://doi.org/10.5090/KJTCS.2011.44.2.169.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009;115(22):5218–27. https://doi.org/10.1002/CNCR.24625.

    Article  PubMed  Google Scholar 

  85. Su S, Scott WJ, Allen MS, et al. Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. J Thorac Cardiovasc Surg. 2014;147(2):747–53. https://doi.org/10.1016/J.JTCVS.2013.10.001.

    Article  PubMed  Google Scholar 

  86. Brunelli A, Pompili C, Koller M. Changes in quality of life after pulmonary resection. Thorac Surg Clin. 2012;22(4):471–85. https://doi.org/10.1016/J.THORSURG.2012.07.006.

    Article  PubMed  Google Scholar 

  87. Handy JR, Asaph JW, Skokan L, et al. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest. 2002;122(1):21–30. https://doi.org/10.1378/CHEST.122.1.21.

    Article  PubMed  Google Scholar 

  88. Handy JR, Asaph JW, Douville EC, Ott GY, Grunkemeier GL, Wu YX. Does video-assisted thoracoscopic lobectomy for lung cancer provide improved functional outcomes compared with open lobectomy? Eur J Cardiothorac Surg. 2010;37(2):451–5. https://doi.org/10.1016/J.EJCTS.2009.07.037.

    Article  PubMed  Google Scholar 

  89. Blom EF, ten Haaf K, Arenberg DA, de Koning HJ. Disparities in receiving guideline-concordant treatment for lung cancer in the United States. Ann Am Thorac Soc. 2020;17(2):186–94. https://doi.org/10.1513/ANNALSATS.201901-094OC.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Coughlin SS, Matthews-Juarez P, Juarez PD, Melton CE, King M. Opportunities to address lung cancer disparities among African Americans. Cancer Med. 2014;3(6):1467–76. https://doi.org/10.1002/CAM4.348.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Lathan CS. Lung cancer care: the impact of facilities and area measures. Transl Lung Cancer Res. 2015;4(4):385–91. https://doi.org/10.3978/J.ISSN.2218-6751.2015.07.23.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Check DK, Albers KB, Uppal KM, et al. Examining the role of access to care: racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members. Lung Cancer. 2018;125:51–6. https://doi.org/10.1016/J.LUNGCAN.2018.09.006.

    Article  PubMed  Google Scholar 

  93. Cykert S, Eng E, Walker P, et al. A system-based intervention to reduce black-white disparities in the treatment of early stage lung cancer: a pragmatic trial at five cancer centers. Cancer Med. 2019;8(3):1095–102. https://doi.org/10.1002/CAM4.2005.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124(5):1946–55. https://doi.org/10.1378/CHEST.124.5.1946.

    Article  PubMed  Google Scholar 

  95. Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer. JAMA Oncol. 2018;4(9):1287–8. https://doi.org/10.1001/JAMAONCOL.2018.1258.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Morrison R, Deeley TJ, Cleland WP. The treatment of carcinoma of the bronchus: a clinical trial to compare surgery and supervoltage radiotherapy. Lancet. 1963;281(7283):683–4. https://doi.org/10.1016/s0140-6736(63)91444-2.

    Article  Google Scholar 

  97. Darling GE, Maziak DE, Inculet RI, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol. 2011;6(8):1367–72. https://doi.org/10.1097/JTO.0B013E318220C912.

    Article  PubMed  Google Scholar 

  98. Timmerman RD, Paulus R, Pass HI, et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial. JAMA Oncol. 2018;4(9):1263. https://doi.org/10.1001/JAMAONCOL.2018.1251.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7. https://doi.org/10.1016/S1470-2045(15)70168-3.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494–503. https://doi.org/10.1016/S1470-2045(18)30896-9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiothoracic Surgery, Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Panagiotis Tasoudis & Gita N. Mody

  2. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Ashley A. Weiner

Authors
  1. Panagiotis Tasoudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashley A. Weiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gita N. Mody
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gita N. Mody .

Editor information

Editors and Affiliations

  1. Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA

    Christina R. MacRosty

  2. Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY, USA

    M. Patricia Rivera

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tasoudis, P., Weiner, A.A., Mody, G.N. (2023). Treatment of Early-Stage (Stage I and II) Non-Small Cell Lung Cancer. In: MacRosty, C.R., Rivera, M.P. (eds) Lung Cancer. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-031-38412-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-38412-7_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-38411-0

  • Online ISBN: 978-3-031-38412-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation